nach oben

Erschienen in:

01.03.2018 | Original Paper

Hypofractionated postmastectomy radiotherapy with helical tomotherapy in patients with immediate breast reconstruction: dosimetric results and acute/intermediate toxicity evaluation

verfasst von: Roberto Orecchia, Damaris Patricia Rojas, Federica Cattani, Rosalinda Ricotti, Luigi Santoro, Anna Morra, Raffaella Cambria, Rosa Luraschi, Samantha Dicuonzo, Sara Ronchi, Alessia Surgo, Veronica Dell’ Acqua, Paolo Veronesi, Francesca De Lorenzi, Cristiana Fodor, Maria Cristina Leonardi, Barbara Alicja Jereczek-Fossa

Erschienen in: Medical Oncology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to evaluate the dosimetry and toxicity of hypofractionation in postmastectomy radiotherapy (PMRT) with intensity-modulated radiotherapy (IMRT) in breast cancer (BC) patients. Stage II–III BC patients with implant-based immediate breast reconstruction received PMRT to the chest wall (CW) and to the infra/supraclavicular nodal region (NR) using a 15-fraction schedule (2.67 Gy/fraction) and helical IMRT (Tomotherapy^® System, Accuray Incorporated, Sunnyvale, CA). A score was assigned to each treatment plan in terms of planning target volume (PTV) coverage of CW and NR and the sparing of the organs at risk (OARs). The total score for each plan was calculated. Toxicity was prospectively assessed according to validated scales. Data from 120 consecutive patients treated in the period 2012–2015 were analysed with a median follow-up from the end of radiotherapy of 13.2 months (range 0.0–35 months). 70.8% (85/120) of the plans had high total scores as a result of an optimal coverage of both CW and RN and optimal sparing of all OARs. The maximum acute toxicity was of grade 2 in 36.7% of the cases. Early late toxicity was mild in the majority of cases. In the study population, helical tomotherapy-based IMRT produced optimal treatment plans in most cases. Acute and late toxicity was mild/moderate. Hypofractionated helical IMRT appears to be safe and feasible in the moderate term for PMRT.

Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;12:1707–16. https://doi.org/10.1016/S0140-6736(11)61629-2.

Berbers J, van Baardwijk A, Houben R, Heuts E, Smidt M, Keymeulen K, Bessems M, Tuinder S, Boersma LJ. Reconstruction: before or after postmastectomy radiotherapy?’ A systematic review of the literature. Eur J Cancer. 2014;50(16):2752–62. https://doi.org/10.1016/j.ejca.2014.07.023.CrossRefPubMed

Krueger EA, Fraass BA, McShan DL, Marsh R, Pierce LJ. Potential gains for irradiation of chest wall and regional nodes with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56(4):1023–37. https://doi.org/10.1016/s0360-3016(03)00183-4.CrossRefPubMed

Ashenafi M, Boyd RA, Lee TK, Lo KK, Gibbons JP, Rosen II, Fontenot JD, Hogstrom KR. Feasibility of postmastectomy treatment with helical TomoTherapy. Int J Radiat Oncol Biol Phys. 2010;77(3):836–42. https://doi.org/10.1016/j.ijrobp.2009.06.027.CrossRefPubMed

Ma J, Li J, Chen J, Zhu C, Cai G, Zhang Z, Guo X, Chen J. Post mastectomy linac IMRT irradiation of chest wall and regional nodes: dosimetry data and acute toxicities. Radiat Oncol. 2013;8:81. https://doi.org/10.1186/1748-717X-8-81.CrossRefPubMedPubMedCentral

Dayes I, Rumble RB, Bowen J, Dixon P, Warde P, Members of the IMRT Indications Expert Panel. Intensity-modulated radiotherapy in the treatment of breast cancer. Clin Oncol (R Coll Radiol). 2012;24(7):488–98. https://doi.org/10.1016/j.clon.2012.05.003.CrossRef

Tsang Y, Ciurlionis L, Kirby AM, Locke I, Venables K, Yarnold JR, Titley J, Bliss J, Coles CE, IMPORT Trial Management Group. Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom. Br J Radiol. 2015;88(1056):20150453. https://doi.org/10.1259/bjr.20150453.CrossRefPubMedPubMedCentral

Caudrelier JM, Truong PT. Role of hypofractionated radiotherapy in breast locoregional radiation. Cancer Radiother. 2015;19(4):241–7. https://doi.org/10.1016/j.canrad.2015.02.012.CrossRefPubMed

Badiyan SN, Shah C, Arthur D, Khan AJ, Freedman G, Poppe MM, Vicini FA. Hypofractionated regional nodal irradiation for breast cancer: examining the data and potential for future studies. Radiother Oncol. 2014;110(1):39–44. https://doi.org/10.1016/j.radonc.2013.12.006.0.CrossRefPubMed

10.

AIRO: Appendice contornamento in: Radiotherapy breast cancer: Indications and guidelines. 2013. http://www.radioterapiaitalia.it/allegato__1222_796.phtml. Accessed 2 Jan 2018.

11.

Motwani SB, Strom EA, Schechter NR, Butler CE, Lee GK, Langstein HN, Kronowitz SJ, Meric-Bernstam F, Ibrahim NK, Buchholz TA. The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66(1):76–82. https://doi.org/10.1016/j.ijrobp.2006.03.040.CrossRefPubMed

12.

Schechter NR, Strom EA, Perkins GH, Arzu I, McNeese MD, Langstein HN, Kronowitz SJ, Meric-Bernstam F, Babiera G, Hunt KK, Hortobagyi GN, Buchholz TA. Immediate breast reconstruction can impact postmastectomy irradiation. Am J Clin Oncol. 2005;28(5):485–94.CrossRefPubMed

13.

Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6. https://doi.org/10.1016/0360-3016(95)00060-C.CrossRefPubMed

14.

Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, Fainsinger R, Aass N. Kaasa S; European Palliative Care Research Collaborative (EPCRC). Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011;41(6):1073–93. https://doi.org/10.1016/j.jpainsymman.2010.08.016.CrossRefPubMed

15.

LENT SOMA tables. Radiother Oncol 1995;35:17–60.

16.

Wang EH, Mougalian SS, Soulos PR, Smith BD, Haffty BG, Gross CP, Yu JB. Adoption of intensity modulated radiation therapy for early-stage breast cancer from 2004 through. Int J Radiat Oncol Biol Phys. 2015;91(2):303–11. https://doi.org/10.1016/j.ijrobp.2014.09.011.CrossRefPubMed

17.

Whitfield GA, Horan G, Irwin MS, Malata CM, Wishart GC, Wilson CB. Incidence of severe capsular contracture following implant-based immediate breast reconstruction with or without postoperative chest wall radiotherapy using 40 Gray in 15 fractions. Radiother Oncol. 2009;90(1):141–7. https://doi.org/10.1016/j.radonc.2008.CrossRefPubMed

18.

Jeevan R, Mennie JC, Mohanna PN, O’Donoghue JM, Rainsbury RM, Cromwell DA. National trends and regional variation in immediate breast reconstruction rates. Br J Surg. 2016;103(9):1147–56. https://doi.org/10.1002/bjs.10161.CrossRefPubMed

19.

Ribuffo D, Monfrecola A, Guerra M, Di Benedetto GM, Grassetti L, Spaziani E, Vitagliano T, Greco M. Does postoperative radiation therapy represent a contraindication to expander-implant based immediate breast reconstruction? An update 2012–2014. Eur Rev Med Pharmacol Sci. 2015;19(12):2202–7.PubMed

20.

Cho BC, Hurkmans CW, Damen EM, Zijp LJ, Mijnheer BJ. Intensity modulated versus non-intensity modulated radiotherapy in the treatment of the left breast and upper internal mammary lymph node chain: a comparative the planning study. Radiother Oncol. 2002;62(2):127–36. https://doi.org/10.1016/S0167-8140(01)00472-8.CrossRefPubMed

21.

Lomax AJ, Cella L, Weber D, Kurtz JM, Miralbell R. Potential role of intensity-modulated photons and protons in the treatment of the breast and regional nodes. Int J Radiat Oncol Biol Phys. 2003;55(3):785–92. https://doi.org/10.1016/S0360-3016(02)04210-4.CrossRefPubMed

22.

Popescu CC, Olivotto IA, Beckham WA, Ansbacher W, Zavgorodni S, Shaffer R, Wai ES, Otto K. Volumetric modulated arc therapy improves dosimetry and reduces treatment time compared to conventional intensity-modulated radiotherapy for locoregional radiotherapy of left-sided breast cancer and internal mammary nodes. Int J Radiat Oncol Biol Phys. 2010;76(1):287–95. https://doi.org/10.1016/j.ijrobp.2009.05.038.CrossRefPubMed

23.

Buchholz TA, Strom EA, Perkins GH, McNeese MD. Controversies regarding the use of radiation after mastectomy in breast cancer. Oncologist. 2002;7(6):539–46. https://doi.org/10.1634/theoncologist.7-6-539.CrossRefPubMed

24.

Yarnold J, Bentzen SM, Coles C, Haviland J. Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. Int J Radiat Oncol Biol Phys. 2011;79(1):1–9. https://doi.org/10.1016/j.ijrobp.2010.08.035.CrossRefPubMed

25.

Davis N, Jyothirmayi R. A Nationwide survey of UK oncologists’ views on the choice of radiotherapy regime for the reconstructed chest wall in breast cancer patients. Int J Breast Cancer. 2017;2017:6385432. https://doi.org/10.1155/2017/6385432.CrossRefPubMedPubMedCentral

26.

Hartford AC, Galvin JM, Beyer DC, Eichler TJ, Ibbott GS, Kavanagh B, Schultz CJ, Rosenthal SA. American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for Intensity-modulated Radiation Therapy (IMRT). Am J Clin Oncol. 2012;35(6):612–7. https://doi.org/10.1097/coc.0b013e31826e0515.CrossRefPubMed

27.

Schubert LK, Gondi V, Sengbusch E, Westerly DC, Soisson ET, Paliwal BR, Mackie TR, Mehta MP, Patel RR, Tomé WA, Cannon GM. Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and topotherapy. Radiother Oncol. 2011;100(2):241–6. https://doi.org/10.1016/j.radonc.2011.01.004.CrossRefPubMed

28.

Staffurth J, Radiotherapy Development Board. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol). 2010;22(8):643–57. https://doi.org/10.1016/j.clon.2010.06.013.CrossRef

29.

Donovan E, Bleakley N, Denholm E, Evans P, Gothard L, Hanson J, Peckitt C, Reise S, Ross G, Sharp G, Symonds-Tayler R, Tait D, Yarnold J, Breast Technology Group. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol. 2007;82(3):254–64. https://doi.org/10.1016/j.radonc.2006.12.008.CrossRefPubMed

30.

Mouw KW, Harris JR. Hypofractionation in the era of modulated radiotherapy (RT). Breast. 2013;22(Suppl 2):S129–36. https://doi.org/10.1016/j.breast.2013.07.024.CrossRefPubMed

31.

Koutcher L, Ballangrud A, Cordeiro PG, McCormick B, Hunt M, Van Zee KJ, Hudis C, Beal K. Postmastectomy intensity modulated radiation therapy following immediate expander-implant reconstruction. Radiother Oncol. 2010;94(3):319–23. https://doi.org/10.1016/j.radonc.2009.12.003.CrossRefPubMed

32.

Chen SA, Hiley C, Nickleach D, Petsuksiri J, Andic F, Riesterer O, Switchenko JM, Torres MA. Breast reconstruction and post-mastectomy radiation practice. Radiat Oncol. 2013;8:45. https://doi.org/10.1186/1748-717X-8-45.CrossRefPubMedPubMedCentral

33.

Budach W, Bölke E, Matuschek C. Hypofractionated radiotherapy as adjuvant treatment in early breast cancer: a review and meta-analysis of randomized controlled trials. Breast Care (Basel). 2015;10(4):240–5. https://doi.org/10.1159/000439007.CrossRef

34.

Freedman GM, Anderson PR, Li J, Klayton T, Li J, Anderson PR, Bleicher RJ, Sigurdson ER, Freedman GM. Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer. Am J Clin Oncol. 2006;29(1):66–70. https://doi.org/10.1097/01.coc.0000197661.09628.03.CrossRefPubMed

35.

Anderson PR, Freedman G, Nicolaou N, Sharma N, Li T, Topham N, Morrow M. Postmastectomy chest wall radiation to a temporary tissue expander or permanent breast implant–is there a difference in complication rates? Int J Radiat Oncol Biol Phys. 2009;74(1):81–5. https://doi.org/10.1016/j.ijrobp.2008.06.1940.CrossRefPubMed

36.

Neal AJ, Torr M, Helyer S, Yarnold JR. Correlation of breast heterogeneity with breast size using 3D CT planing and dose volume histograms. Radiother Oncol. 1995;34:210–8. https://doi.org/10.1016/0167-8140(95)01521-H.CrossRefPubMed

37.

Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR, START Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–94. https://doi.org/10.1016/S1470-2045(13)70386-3.CrossRefPubMed

38.

Anderson Mehta VK, Goffinet D. Postmastectomy radiation therapy after TRAM flap breast reconstruction. Breast J. 2004;10(2):118–22.CrossRef

39.

Mignot F, Ajgal Z, Xu H, Geraud A, Chen JY, Mégnin-Chanet F, Kirova Y. Concurrent administration of anti-HER2 therapy and radiotherapy: systematic review. Radiother Oncol. 2017;124(2):190–9. https://doi.org/10.1016/j.radonc.2017.07.006.CrossRefPubMed

40.

Meattini I, Cecchini S, Muntoni C, Scotti V, De Luca Cardillo C, Mangoni M, Bonomo P, Nori J, Casella D, Simoncini R, Orzalesi L, Bianchi S, Livi L. Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series. Med Oncol. 2014;31(4):891. https://doi.org/10.1007/s12032-014-0891-x.CrossRefPubMed

41.

Belkacémi Y, Gligorov J, Ozsahin M, Marsiglia H, De Lafontan B, Laharie-Mineur H, Aimard L, Antoine EC, Cutuli B, Namer M, Azria D. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol. 2008;19(6):1110–6. https://doi.org/10.1093/annonc/mdn029.CrossRefPubMed

42.

Haciislamoglu E, Colak F, Canyilmaz E, Dirican B, Gurdalli S, Yilmaz AH, Yoney A, Bahat Z. Dosimetric comparison of left-sided whole-breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and volumetric arc therapy. Phys Med. 2015;31(4):360–7. https://doi.org/10.1016/j.ejmp.2015.02.005.CrossRefPubMed

43.

VargoJA Beriwal S. RTOG chest wall contouring guidelines for post-mastectomy radiation therapy: is it evidence-based? Int J Radiat Oncol Biol Phys. 2015;93(2):266–7. https://doi.org/10.1016/j.ijrobp.2015.03.001.CrossRef

44.

Fontanilla HP, Woodward WA, Lindberg ME, Kanke JE, Arora G, Durbin RR, Yu TK, Zhang L, Sharp HJ, Strom EA, Salehpour M, White J, Buchholz TA, Dong L. Current clinical coverage of Radiation Therapy Oncology Group defined target volumes for post-mastectomy radiation therapy. Pract Radiat Oncol. 2012;2:201–9. https://doi.org/10.1016/j.prro.2011.10.001.CrossRefPubMed

45.

Caudrelier JM, Morgan SC, Montgomery L, Lacelle M, Nyiri B, Macpherson M. Helical tomotherapy for locoregional irradiation including the internal mammary chain in left-sided breast cancer: dosimetric evaluation. Radiother Oncol. 2009;90(1):99–105. https://doi.org/10.1016/j.radonc.2008.09.028.CrossRefPubMed

Titel: Hypofractionated postmastectomy radiotherapy with helical tomotherapy in patients with immediate breast reconstruction: dosimetric results and acute/intermediate toxicity evaluation
verfasst von: Roberto Orecchia
Damaris Patricia Rojas
Federica Cattani
Rosalinda Ricotti
Luigi Santoro
Anna Morra
Raffaella Cambria
Rosa Luraschi
Samantha Dicuonzo
Sara Ronchi
Alessia Surgo
Veronica Dell’ Acqua
Paolo Veronesi
Francesca De Lorenzi
Cristiana Fodor
Maria Cristina Leonardi
Barbara Alicja Jereczek-Fossa
Publikationsdatum: 01.03.2018
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 3/2018
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-018-1095-6

Springer Medizin

Hypofractionated postmastectomy radiotherapy with helical tomotherapy in patients with immediate breast reconstruction: dosimetric results and acute/intermediate toxicity evaluation

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Long-term survival with modern therapeutic agents against metastatic melanoma—vemurafenib and ipilimumab in a daily life setting

Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens

Genetic polymorphism of calcium-sensing receptor in women with breast cancer

Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer

The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma

A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie